In recent years, with the in-depth study of PD-1/PD-L1 related pathways, great progress has been made in cancer immunotherapy. However, the immunotherapy regimen for mccRCC is still controversial in clinical practice.

A 50-year-old man with mccRCC complicated with renal venous tumor thrombus from 2019 to present, including surgical treatment, targeted therapy and the combined treatment regimen of “Tislelizumab combined with Sunitinib”. Although he experienced a roller coaster of adverse reactions during treatment, the patient's prognosis was good.

Tislelizumab combined with Sunitinib is safe and effective in the Treatment of mccRCC.

Tislelizumab

mccRCC

Immunotherapy

Targeted therapy

© 2024 The Authors. Published by Elsevier Inc.